Key facts
- Pregbio’s last known valuation is $14.4M (Sep 2022).
- It has raised $2.2M; the latest was Early Stage VC in Dec 2024.
- Notable investors include Goldport Capital, ASB Ventures, Jiadao Private Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Pregbio
- ·The full record, as it builds
Funding rounds
No funding rounds for Pregbio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pregbio
Developer of rapid diagnostic reagents in perinatal-related fields. The company focuses on biomarker development for testing, preterm birth, early screening and diagnosis of preeclampsia, non-invasive prenatal screening for fetal malformation, enabling pregnant woman to have healthy baby.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2020
- Website
- pregbio.com/
- Ownership
- Privately Held (backing)
Pregbio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pregbio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pregbio in its N-PORT filings yet. We sweep new filings monthly.